Beneficient

As of May 10, 2024, Beneficient is considered overvalued and risky, with poor financial metrics including a P/E ratio of 0.0079 and a year-to-date stock return of -62.26%, significantly underperforming compared to its peers and the S&P 500.

As of April 28, 2025, the market trend is mildly bearish, influenced by daily moving averages and Bollinger Bands, despite some counterbalance from the MACD, with overall indicators showing a lack of strong bullish momentum.

Beneficient is a micro-cap company in the Capital Markets industry, reporting net sales of $0 million and a net profit loss of $10 million as of December 2024, with a market cap of $2.55 million. Key financial metrics include a P/E ratio of 0.00 and a return on equity of -193.53%.

As of Jun 18, Beneficient has a market capitalization of 2.55 million, with net sales of 1.05 million and a net profit of -151.74 million over the latest four quarters. As of Mar 24, shareholder's funds are at -234.35 million and total assets are 368.50 million.